These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. Law AB; Ryan G; Lade S; Prince HM Int J Hematol; 2010 Mar; 91(2):347-8; author reply 349. PubMed ID: 20146033 [No Abstract] [Full Text] [Related]
5. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Powles T; Stebbing J; Montoto S; Nelson M; Gazzard B; Orkin C; Webb A; Bower M Blood; 2007 Dec; 110(12):4132-3. PubMed ID: 18024800 [No Abstract] [Full Text] [Related]
6. Complete remission in 4 patients with human herpesvirus 8-associated multicentric Castleman disease using rituximab and liposomal doxorubicin, a novel chemotherapy combination. Peker D; Martinez AE; Schwartz MA; Cusnir M Clin Adv Hematol Oncol; 2012 Mar; 10(3):204-6. PubMed ID: 22402431 [No Abstract] [Full Text] [Related]
7. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054 [TBL] [Abstract][Full Text] [Related]
8. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920 [TBL] [Abstract][Full Text] [Related]